Quant Mid Cap Fund completely exited its positions in Anthem Biosciences and Lenskart Solutions in July, while adding Cochin Shipyard and four other stocks to its portfolio during the month, according to monthly portfolio data disclosed by ACE MF.
The fund sold 47.86 lakh shares of Anthem Biosciences from its portfolio worth a market value of Rs 368 crore. It sold 9.28 lakh shares of Lenskart Solutions worth a market value of Rs 47 crore.
Also Read | Mutual funds raise IT exposure to 6.6% in July after record low. Is sentiment towards tech improving?
The mid cap fund added five new stocks in its portfolio in the same time period. It added 2.73 lakh shares of Cochin Shipyard in its portfolio in July. The fund added 11.62 lakh shares of UPL, 8 lakh shares of IPCA Laboratories in its portfolio in the month of July. The other two stocks added by the fund in its portfolio were Ambuja Cements (6.30 lakh shares), Glaxosmithkline Pharmaceuticals (1 lakh shares).
The fund increased its exposure to nearly six stocks in July. It added around 6.62 lakh shares of Adani Energy Solutions, taking its total holding to 17.29 lakh shares in July from 10.67 lakh shares in June.
The fund also added around 5.89 lakh shares of Indus Towers, taking its total holding to 1.23 crore shares in July. The other four stocks where it increased its stake were LG Electronics, JSW Infrastructure, L&T Technology Services and Premier Energies.
Aurobindo Pharma was the only stock where the fund reduced its stake in July. Nearly 2.64 lakh shares of this stock were sold from the portfolio, taking the total share count to 51.03 lakh in July compared to 53.67 lakh in June.
In July, the fund had 23 stocks in its portfolio compared to 20 stocks in the previous month. The fund had an AUM of Rs 8,106 crore as of July 2026.
As a percentage to NAV, the fund had the highest allocation in Aurobindo Pharma of around 9.95%, followed by Lloyds Metals & Energy and Tata Communications where the allocation was 9.27% and 8.50% respectively.
The primary investment objective of the scheme is to seek to generate capital appreciation & provide long-term growth opportunities by investing in a portfolio of Mid Cap companies. The performance is benchmarked against Nifty Midcap 150 - TRI.
The fund is managed by Sandeep Tandon, Ankit Pande, Varun Pattani, Ayusha Kumbhat, Yug Tibrewal, Sameer Kate, Sanjeev Sharma.
Also Read | Sammaan Capital shares fall 4% after Q1 profit declines 27% to Rs 243 crore, revenue drops 31%
According to the monthly factsheet, the portfolio of this mid cap fund is designed to capture the dynamism, innovation, and earnings momentum that define the mid-cap universe. During the month, exposure to Index futures (+7.65%) and IT (1.97%) was increased while Healthcare (-2.94%) was reduced. Mid-caps are in a favourable phase supported by improving fundamentals, the factsheet said further.
( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
If you have any mutual fund queries, message on ET Mutual Funds on Facebook/Twitter. We will get it answered by our panel of experts. Do share your questions on ETMFqueries@timesinternet.in alongwith your age, risk profile, and Twitter handle .
